Estradiol promotes the rewarding effects of nicotine in female rats

Rodolfo J. Flores, Joseph A. Pipkin, Kevin P. Uribe, Adriana Perez, and Laura E. O’Dell

Department of Psychology, The University of Texas at El Paso, 500 West University Avenue, El Paso, TX 79968

Abstract

It is presently unclear whether ovarian hormones, such as estradiol (E2) promote the rewarding effects of nicotine in females. Thus, we compared extended access to nicotine intravenous self-administration (IVSA) in intact male, intact female, and OVX female rats (Study 1) as well as OVX females that received vehicle or E2 supplementation (Study 2). The E2 supplementation procedure involved a 4-day procedure involving 2 days of vehicle administration and 2 days of E2 administration. Two doses of E2 (25 or 250 ug) were assessed in separate groups of OVX females in order to examine the dose-dependent effects of this hormone on the rewarding effects of nicotine. The rats were given 23-hour access to nicotine IVSA using an escalating dose regimen (0.015, 0.03, and 0.06 mg/kg/0.1 ml). Each dose was self-administered for 4 days with 3 intervening days of nicotine abstinence. The results revealed that intact females displayed higher levels of nicotine intake as compared to males. Also, intact females displayed higher levels of nicotine intake versus OVX females. Lastly, our results revealed that OVX rats that received E2 supplementation displayed a dose-dependent increase in nicotine intake as compared to OVX rats that received vehicle. Together, our results suggest that the rewarding effects of nicotine are enhanced in female rats via the presence of the ovarian hormone, E2.

Keywords

sex differences; tobacco; estradiol; self-administration; rat

1. Introduction

Epidemiological reports suggest that women are more susceptible to tobacco use than men. This is based on previous studies showing that women consume more tobacco products and they have a harder time quitting smoking than men [1-2]. Nicotine has been identified as the main compound that motivates tobacco use, and clinical reports indicate that women rate nicotine as more pleasurable than men [3]. In addition, women that use tobacco regularly...
report higher positive subjective effects following presentation of smoking-related stimuli as compared to men [1, 4]. Clinical reports have also shown that nicotine replacement therapy is a less effective smoking cessation therapy in women as compared to men [5]. Despite the evidence suggesting that nicotine is a strong reinforcing agent in women, very little is known about the underlying mechanisms that promote tobacco use in females.

Reviews of pre-clinical studies have provided converging lines of evidence suggesting that the rewarding effects of nicotine are greater in adult female versus male rodents [1, 6-8]. One of the first studies in this area demonstrated that female adult rats display faster acquisition rates of low doses of nicotine IVSA than males [9]. The latter study also revealed that adult females reach a higher break point for nicotine infusions on a PR schedule of reinforcement than males. Subsequent studies from the same laboratory also showed that female rats display 2-fold higher levels of nicotine IVSA as compared to males in the presence of a visual stimulus that signals a nicotine infusion [10]. Female rats also display higher levels of nicotine intake in procedures involving oral [11] and IV self-administration procedures under both short [12] and long [13] access conditions. Female rodents also display conditioned place preference (CPP) produced by nicotine that is more robust across a wider range of doses as compared to male rats [14] and mice [15]. However, we acknowledge another report showing that nicotine-induced CPP is larger in male versus female rats [16].

Clinical reports have suggested that ovarian hormones, such as estrogen, promote tobacco use in women. Indeed, high levels of estrogen are positively correlated with a greater sensitivity to the rewarding effects of nicotine in women [17]. Consistent with the latter finding, women display higher levels of nicotine craving and relapse rates during the follicular phase of the menstrual cycle when estrogen levels are highest [18]. Although these studies suggest that estrogen promotes tobacco use in women, the role of specific ovarian hormones in promoting nicotine reward has not been examined in pre-clinical animal studies.

The goal of the present study was to examine the role of the ovarian hormone, E2 in promoting the rewarding effects of nicotine in female rats. Nicotine IVSA was compared in intact male, intact female, and OVX female rats (Study 1) as well as OVX female rats that received vehicle or E2 supplementation (Study 2). Two doses of E2 were included to examine the dose-dependent effects of this hormone on nicotine IVSA. We used an extended-access model of IVSA whereby rats were given 23-hour access to increasing doses of nicotine separated by 3-day periods of drug abstinence. We hypothesized that E2 plays a primary role in modulating nicotine reward. This is based on previous studies showing that OVX females display a reduction in cocaine IVSA that is normalized to intact female levels following E2 supplementation [19]. Also, another report revealed that OVX rats that received E2 supplementation displayed greater motivation to obtain cocaine relative to OVX rats that received vehicle [20].
2. Materials and methods

2.1. Subjects

Male and female Wistar rats were obtained from an out-bred stock of animals (Harlan, Inc., Indianapolis, IN). On post-natal day (PND) 21, the rat pups were weaned and paired with a same-sex littermate until PND 60, at which point they were individually housed for the remainder of the study. The rats were housed in a humidity- and temperature-controlled (22°C) vivarium on a 12-hour light/dark cycle (lights off at 6:00 am and on at 6:00 pm). Prior to beginning the experiment, the rats were handled for 5 days and they had ad libitum access to food and water. The UTEP Institutional Animal Care and Use Committee approved our procedures prior to experimentation.

2.2. Overall experimental design

This project consisted of 2 studies with different experimental goals (see inset below). Study 1 compared nicotine intake in intact male (n=10), intact female (n=14), and OVX female (n=9) rats. Both male and female rats received a sham surgery at PND 60 as a control procedure for the OVX surgeries. Study 2 examined the role of E2 in modulating the rewarding effects of nicotine in OVX females that received vehicle (peanut oil; OVX-VEH; n=8) or an E2 supplementation procedure involving 2 different doses in separate groups of animals (E2-25 ug (n=8) and E2-250 ug (n=10)).
<table>
<thead>
<tr>
<th>Experimental Days</th>
<th>1</th>
<th>2-14</th>
<th>15-19</th>
<th>20</th>
<th>21-24</th>
<th>25-42</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study 1: Sex differences</td>
<td>SHAM surgery</td>
<td>Recovery and rest period</td>
<td>Food and water training</td>
<td>Catheter surgery</td>
<td>Recovery</td>
<td>Nicotine IVSA</td>
</tr>
<tr>
<td>Males</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Females</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OVX Females</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study 2: Role of E2</td>
<td>OVX surgery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OVX-VEH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OVX-E2-25 ug</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OVX-E2-250 ug</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SHAM surgery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recovery and rest period</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Food and water training</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Catheter surgery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recovery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.015 mg/kg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abstinence</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 Days</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.03 mg/kg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abstinence</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 Days</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.06 mg/kg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abstinence</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 Days</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 Days</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 Days</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 Days</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Continued 4-day cycles of vehicle and E2 supplementation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
2.3. Operant procedures

The present study utilized extended access procedures that are established in our laboratory [21-22]. IVSA was assessed in standard operant chambers (MED associates, St. Albans, VT) that were kept on the same light cycle as the holding room. Operant sessions were conducted using 2 retractable levers (active and inactive) that extended 2.5 cm into the chamber. A 28 V white cue light was located above the active lever and a dummy light was above the inactive lever. A pellet dispenser mounted between the inactive and active lever allowed the rats to nose-poke for food. A separate hole located in the back of the chamber allowed the rats to nose-poke for water that was released into an adjacent metal dipper cup. The exit port of the catheter fitting was connected to a polyethylene tubing within a metal spring that was connected to a liquid swivel above the operant chamber.

During the first 4 days of operant procedures, the rats received food and water training. The rats were allowed to nose-poke for the delivery of food pellets (45 mg; Bio-Serv; Frenchtown, NJ) or water (0.1 mL) on a fixed-ratio 1 (FR-1) schedule of reinforcement. Throughout the operant procedures, the rats were removed from the chambers between 11:00 am and 12:00 pm in order to clean the cages and replenish the water and food levels. Immediately after being removed from the chambers, the rats were weighed and placed individually into their home cage.

On the first day of IVSA, the rats were presented with a novel active and inactive lever at 12:00 pm. The rats were given access to various doses of nicotine IVSA on an FR-1 schedule of reinforcement using an escalating dose regimen of nicotine (0.015, 0.03, and 0.06 mg/kg/0.1 mL infusion; base). When the active lever was pressed, the nicotine solution was delivered at a rate of 0.1 mL per second. At the onset of the 1-second infusion, a cue light was illuminated above the lever for 20 seconds. This was followed by a 20-second time out period. Responses on the inactive lever had no scheduled consequences. The nicotine solutions were prepared daily based on the animals’ weight from the previous day. A nicotine stock solution was prepared for each IVSA dose using (-) nicotine hydrogen tartrate (Sigma-Aldrich, St. Louis, MO) dissolved in 0.9% sterile saline (pH of 7.4). Each dose of nicotine was administered in a 4-day cycle with 3 intervening days of drug abstinence. During the 3-day abstinence period, the rats were individually housed in their home cage with ad libitum food and water.

2.4. Surgical procedures

At PND 65, the rats were anesthetized with an isoflurane/oxygen vapor mixture (1-3%) and were prepared with jugular catheters, as described previously [21-22]. Following surgery, the rats were allowed to recover for 4 days and the catheters were flushed daily with a 0.2 mL infusion of an antibiotic solution containing Timentin (100 mg/ml) and heparinized saline (30 USP units/mL). Prior to nicotine IVSA, the catheter patency was verified using a 0.1 mL IV infusion of the short-acting barbiturate Brevital® sodium (10 mg/mL). Patency tests were also conducted when aberrant shifts in behavior were detected, and non-patent animals were excluded from the study.
Some female rats received surgical removal of ovarian tissue at PND 45-46, as described previously [14]. In order to assess the role of E2 in modulating the rewarding effects of nicotine, we removed ovarian tissue and immediately began an E2 supplementation procedure. The OVX procedure was done at PND 45-46 based on previous work in our laboratory showing that adult female rats that received OVX procedures at PND 45 display a reduction in the rewarding effects of nicotine [14] and a suppression of anxiety-like behavior and stress-associated gene expression during nicotine withdrawal [23-24]. These studies suggest that after PND 45 ovarian hormones play a key role in modulating the behavioral effects and molecular changes produced by nicotine.

2.5. E2 supplementation procedure

The rats in Study 2 received a 4-day E2 supplementation procedure that began the day after the OVX surgery. Control OVX females received repeated vehicle injections (peanut oil). OVX females that received the E2 supplementation procedure received 2 days of a 0.2 ml bolus injection of E2 (25 or 250 ug) and 2 days of vehicle injections. The E2 supplementation procedure was repeated 4 times prior to and throughout IVSA testing. The injections were administered each day between 11:00 am and 12:00 pm when the animals were removed from the operant chambers. This supplementation procedure is believed to mimic normal E2 cycling patterns in intact female rats [25]. The latter study was also used to guide our selection of a low physiological dose of E2 (25 ug) and a significantly higher dose (250 ug) that was expected to produce strong pharmacological effects.

2.6. Statistics

Average nicotine intake was calculated on a daily basis across different doses of nicotine. Each study was analyzed separately using a repeated measures analysis of variance (ANOVA) with group as the between-subjects factor and dose as a within-subjects factor. Where significant interactions were observed, post-hoc comparisons were made between groups.

3. Results

3.1. Study 1

Figure 1 depicts nicotine IVSA (mg/kg) in intact male, intact female, and OVX female rats. The panel on the left reflects daily intake, and the panel on the right reflects mean intake of each dose. Overall, the results revealed that female rats display dose-dependently higher levels of nicotine intake as compared to intact males and OVX females. Our analysis of daily intake in the left panel revealed a 3-way interaction between group, dose, and day ($F_{(12,180)}=2.2$, $P<0.01$). Specifically, intact females display higher levels of nicotine intake as compared to both intact males and OVX females on Days 5-6 and 11-12 (*$P<0.05$). Also, intact females display higher levels of nicotine intake as compared to OVX females on Day 7, 8, and 10 (†$P<0.05$). Our analysis of mean intake in the right panel revealed a 2-way interaction between dose and day ($F_{(4,60)}=3.7$, $P<0.01$). Intact females display higher levels of nicotine intake as compared to both intact males and OVX females at the 0.06 mg/kg dose of nicotine (*$P<0.05$). Also, intact females display higher levels of nicotine intake as compared to OVX females at the 0.015 and 0.03 mg/kg dose of nicotine (†$P<0.05$). Our
group differences in Study 1 do not appear to be related to inactive lever pressing, since there were no differences in mean total responses on the inactive lever across IVSA days in intact male (17.9±4.9), intact female (24.9±5.7), and OVX female (27.5±4.7) rats ($F_{(1,20)}=1.0$, $P=\text{ns}$).

### 3.2. Study 2

Figure 2 depicts nicotine IVSA (mg/kg) in OVX female rats that received vehicle or E2 supplementation. The panel on the left reflects daily intake, and the panel on the right reflects mean intake of each dose. Overall, the results revealed that OVX female rats that received the high dose of E2 display greater nicotine intake as compared to OVX females that received vehicle and the low dose of E2. Our analysis of daily intake in the left panel revealed a 3-way interaction between group, dose, and day ($F_{(12,138)}=2.2$, $P<0.01$). Specifically, OVX female rats that received the high dose of E2 display greater nicotine intake as compared to OVX female that received vehicle on Day 1-6, 8, and 10-11 (*$P<0.05$). Also, OVX female rats that received the low dose of E2 displayed greater nicotine intake as compared to vehicle controls on Day 3 (*$P<0.05$). With regard to dose-dependent effects of E2, OVX female rats that received the high dose of E2 displayed higher levels of nicotine intake as compared to rats that received the low dose of this hormone on Day 4, 7, and 9-10 (†$P<0.05$). Our analysis of mean intake in the right panel revealed that OVX female rats that received the high dose of E2 displayed greater nicotine intake as compared to vehicle controls at each dose of nicotine (*$P<0.05$). Also, OVX females that received the low dose of E2 displayed greater nicotine intake as compared to vehicle controls at the 0.015 mg/kg dose of nicotine (†$P<0.05$). With regard to dose-dependent effects of E2, OVX female rats that received the high dose of E2 displayed greater nicotine intake as compared to rats that received the low dose of E2 at the 0.03 mg/kg dose of nicotine (†$P<0.05$). Our group differences do not appear to be related to disparities in inactive lever pressing, since there were no differences in mean total responses on the inactive lever across IVSA days in OVX female rats that received vehicle (30.8±7.4), E2 25 ug (25.6±5.8), and E2 250 ug (38.8±9.5) administration ($F_{(1,3)}=0.7$, $P=\text{ns}$).

### 4. Discussion

In summary, the present study revealed that the rewarding effects of nicotine are greater in intact female versus male rats. The latter effect appears to be hormone dependent, as the strong rewarding effects of nicotine observed in intact females are reduced in female rats lacking ovaries. The unique contribution of this report is that E2 supplementation increases nicotine intake in OVX females as compared vehicle controls.

Our finding that intact females display greater rewarding effects of nicotine than males is consistent with previous reports. In fact, there are now several reports showing that adult female rats display greater rewarding effects of nicotine across an array of IVSA [9-13] and CPP (14-15) experimental conditions. However, we acknowledge other reports showing that adult female rats display similar [26] or lower [27] levels of nicotine intake as compared to males. The notion that the rewarding effects of nicotine are greater in females is also supported in previous studies that compared sex differences in nicotine reward during the

*Behav Brain Res. Author manuscript; available in PMC 2017 July 01.*
adolescent period of development. For example, adolescent female rats acquired nicotine IVSA at lower doses [28] and display higher levels of nicotine intake under extended access conditions [29] as compared to males. Another series of studies revealed that female rats that initiated nicotine IVSA during adolescence display an escalation of nicotine intake into adulthood, but this effect was not observed in males [30-31]. The present study contributes to a large body of literature suggesting that adult female rats are more sensitive to the rewarding effects of nicotine than males.

Our finding that OVX rats display reduced nicotine IVSA as compared to intact females suggests that ovarian hormones mediate the rewarding effects of nicotine in female rats. This is consistent with previous findings in our laboratory showing that OVX rats do not display CPP across an array of nicotine doses [14]. Similarly, OVX female rats do not display CPP produced by ethanol [32] and they acquire IVSA of cocaine [33-34] and heroin [35] at slower rates than intact females. These findings suggest that the rewarding effects of drugs of abuse are modulated by the presence of ovarian hormones.

The unique contribution of the present study is that E2 supplementation dose-dependently increased the rewarding effects of nicotine in female rats lacking ovarian hormones. The finding that the strong rewarding effects of nicotine are normalized in OVX rats that receive E2 supplementation suggests that E2 is an ovarian hormone that modulates the rewarding effects of nicotine. E2 has been identified as an ovarian hormone that modulates the rewarding effects of drugs of abuse, such as cocaine [36]. Indeed, previous reports have revealed that OVX rats that received E2 supplementation acquired cocaine [33-34, 37] and heroin [35] IVSA more readily as compared to OVX rats that received vehicle. Our findings extend the literature by showing that E2 also modulates the rewarding effects of nicotine.

It has been suggested that E2 promotes nicotine reward via an enhancement of dopamine transmission in the mesolimbic pathway, which originates in the ventral tegmental area and terminates in several forebrain structures including the striatum and nucleus accumbens (NAcc) [38-40]. OVX female rats display a reduction in synaptic levels of dopamine in the striatum that is normalized by following E2 supplementation [41]. Also, acute administration of E2 enhances dopamine release via activation E2 receptors in the striatum, in female but not male rats [42-43]. It has been posited that E2 receptors in the NAcc are located on the terminals of inhibitory gamma-aminobutyric acid (GABA) medium spiny neurons, such that activation of E2 receptors disinhibits GABA and increases dopamine release in the striatum [44]. Thus, it is possible that E2 promotes the rewarding effects of nicotine via an increase in dopamine transmission. We also recognize the importance of other ovarian hormones, such as progesterone that has been shown to play a role in modulating drug use in females [6, 17]. Indeed, a previous study revealed that peak plasma levels of progesterone are negatively correlated with nicotine IVSA in adolescent female rats [28]. Future studies are needed to examine the intricate relationship between E2 and progesterone in modulating the rewarding effects of nicotine in females.

The present findings provide important clinical implications regarding tobacco use in females. The finding that E2 promotes the rewarding effects of nicotine in suggests that E2 may play a central role in promoting tobacco use in women. Indeed, clinical studies have
shown that women in the follicular phase of the menstrual cycle report greater positive subjective effects of nicotine [45]. Thus, it is possible that high levels of estrogen promote nicotine use and relapse. Future work is needed at the preclinical and clinical level to help elucidate the role of ovarian hormones, such as E2, in promoting nicotine use in females.

Acknowledgements

The authors thank Christian Tejeda, Tiahna Ontiveros, Sara Woldemarian, Cecilia Hinojosa, Victoria Edwards, and Bryan Cruz for their technical assistance. This research was supported by the National Institute on Drug Abuse (R01-DA021274), the Diversity-promoting Institutions Drug Abuse Research Program (R24-DA029989), and the SMART:MINDS Research Experience for Undergraduates Training Program (R25-DA033613). This project was also supported by the National Institute of Minority Health Disparities (G12MD007592) as part of the UTEP Border Biomedical Research Center.

References


### HIGHLIGHTS

- Greater rewarding effects of nicotine in female versus male rats.
- Greater rewarding effects of nicotine in intact female versus OVX female rats.
- Greater nicotine reward in E2-supplemented OVX female rats versus controls.
This figure depicts nicotine IVSA depicted as daily intake (left panel) and mean intake (right panel) in intact male (n=10), intact female (n=14), and OVX female (n=9) rats from Study 1. Rats were given 23-hour access to escalating doses of nicotine (0.015, 0.03 and 0.06 mg/kg) for 4 consecutive days separated by 3 days of drug abstinence. Intact female rats displayed higher levels of nicotine intake as compared to males and OVX females. The asterisks (*) denote significantly higher intake in intact females as compared to both intact males and OVX females, and the daggers (†) denote higher intake in intact females as compared to OVX females (P≤0.05).
This figure depicts nicotine IVSA depicted as daily intake (left panel) and mean intake (right panel) in OVX female rats that received vehicle (OVX-VEH; n=8) or E2 supplementation at a low (OVX-E2 25 ug; n=8) or high (OVX-E2 250 ug; n=10) dose of this hormone in Study 2. OVX females that received the high dose of E2 displayed higher levels of nicotine intake as compared vehicle controls and OVX females that received the low dose of E2. The asterisks (*) denote significantly higher intake in OVX females that received E2 as compared to vehicle controls, and the daggers (†) denote higher levels of intake in OVX females that received the high versus low dose of E2 (P≤0.05).